Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.08.2020 | Case report

Ustekinumab

No response and loss of response: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Truyens M, et al. Efficacy of Ustekinumab intensification and re-induction in Crohn's disease patients with insufficient or loss of response. United European Gastroenterology Journal 7 (Suppl.): 645 abstr. P1134, No. 8, Oct 2019. Available from: URL: http://doi.org/10.1177/2050640619854671 [abstract] Truyens M, et al. Efficacy of Ustekinumab intensification and re-induction in Crohn's disease patients with insufficient or loss of response. United European Gastroenterology Journal 7 (Suppl.): 645 abstr. P1134, No. 8, Oct 2019. Available from: URL: http://​doi.​org/​10.​1177/​2050640619854671​ [abstract]
Metadaten
Titel
Ustekinumab
No response and loss of response: 3 case reports
Publikationsdatum
01.08.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-81943-9

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Dexamethasone

Case report

Escitalopram

Case report

Bleomycin